Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study

INTRODUCTION: In the EDITION clinical trial programme, patients with type 2 diabetes mellitus (T2DM) receiving insulin glargine (IGlar) U300 required 10–15% more insulin than those receiving IGlar U100. This study sought to determine whether this difference was apparent in real-world practice. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Duque, Natalia, Artime, Esther, Romera, Irene, Lebrec, Jeremie, Díaz, Silvia, Rubio, Miriam, Sicras-Mainar, Antoni, Carretero-Anibarro, Enrique, Mundet, Xavier, Gorgojo-Martínez, Juan J., Reviriego, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280027/
https://www.ncbi.nlm.nih.gov/pubmed/34052987
http://dx.doi.org/10.1007/s12325-021-01773-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280027/
https://www.ncbi.nlm.nih.gov/pubmed/34052987
http://dx.doi.org/10.1007/s12325-021-01773-z

Ejemplares similares